Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Neuroscientific Biopharmaceuticals Ltd. ( (AU:NSB) ).
NeuroScientific Biopharmaceuticals Ltd has announced the commencement of a Special Access Program for treating fistulising Crohn’s disease using StemSmart™ MSC therapy. The program, which marks a significant step in the company’s operations, involves treating the first patient with four weekly treatments starting around June 2, 2025. This initiative is part of the company’s ongoing efforts to acquire StemSmart™ technology from Isopogen WA Ltd, with the potential to progress to a Phase 1/2 clinical trial if successful. The company is also preparing for a general meeting to secure additional funding, which will bolster its strategic positioning in the biologics market.
More about Neuroscientific Biopharmaceuticals Ltd.
NeuroScientific Biopharmaceuticals Ltd is a company operating in the biopharmaceutical industry, focusing on developing next-generation biologics. Their primary products include the StemSmart™ MSC therapy, derived from adult human donor bone marrow, aimed at treating serious and life-threatening conditions such as Crohn’s disease, kidney transplants, lung disorders, and GvHD. The company is strategically positioning itself at the forefront of innovative biologics with a focus on addressing significant global markets.
Average Trading Volume: 352,753
Technical Sentiment Signal: Buy
Current Market Cap: A$7.09M
For an in-depth examination of NSB stock, go to TipRanks’ Stock Analysis page.